BiotechTube
Stellular Bio

Stellular Bio

Cambridge, United States· Est.
stellularbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.5M

Overview

Stellular Bio is developing an off-the-shelf, platelet-derived biologic therapy targeting the large and growing market for ocular surface diseases. The company's PRB platform seeks to combine the polypharmacology of platelet-rich plasma with the consistency and scalability of an engineered product. With a Series 1 financing round closed and a leadership team experienced in biotech development and manufacturing, Stellular is positioned to advance its lead candidate into clinical trials. The initial focus is on severe dry eye disease, with plans to expand into broader OSD indications.

OphthalmologyOcular Surface Disease

Technology Platform

Platelet-derived Regenerative Biologic (PRB): An engineered, off-the-shelf biologic designed to deliver the polypharmacology of hundreds of platelet-derived active substances. Features a proprietary, scalable manufacturing process aimed at being well-characterized, reproducible, and tunable via iPSC engineering.

Funding History

1
Total raised:$4.5M
Seed$4.5M

Opportunities

The large and growing OSD market, driven by aging and increased screen time, presents a multi-billion dollar opportunity.
An effective, standardized regenerative therapy could capture significant share in the severe patient segment where current anti-inflammatory and lubricant treatments are inadequate.
The platform's potential for expansion into other corneal repair indications and tunability via iPSC engineering provides long-term pipeline optionality.

Risk Factors

High clinical development risk as a preclinical company, with unproven efficacy and safety of its novel PRB platform in humans.
Faces significant competition in the crowded dry eye market from large pharma and must secure favorable reimbursement for a likely high-cost biologic.
Future financing is dependent on achieving clinical milestones in a challenging capital environment.

Competitive Landscape

Stellular competes in the dry eye/OSD market with large pharma (e.g., Allergan/AbbVie, Novartis, Bausch + Lomb) selling anti-inflammatories and lubricants, and with specialty biotechs developing novel mechanisms. Its direct competitive approach is against autologous blood-derived products (serum, PRP eye drops), which it aims to displace with a superior, standardized, off-the-shelf product. It may also compete with other regenerative approaches in development.

More companies in Biologics / Biosimilars →More companies in United States →